PL2448600T3 - Związki ukierunkowane na kationoniezależny receptor mannozo-6-fosforanu - Google Patents

Związki ukierunkowane na kationoniezależny receptor mannozo-6-fosforanu

Info

Publication number
PL2448600T3
PL2448600T3 PL10727003.5T PL10727003T PL2448600T3 PL 2448600 T3 PL2448600 T3 PL 2448600T3 PL 10727003 T PL10727003 T PL 10727003T PL 2448600 T3 PL2448600 T3 PL 2448600T3
Authority
PL
Poland
Prior art keywords
cation
compounds targeting
phosphate receptor
independent mannose
mannose
Prior art date
Application number
PL10727003.5T
Other languages
English (en)
Inventor
Marcel Garcia
Alain Morere
Magali Gary-Bobo
Martine Cerutti
Cheikh Khaled El
Ilaria Basile
Philippe Nirde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2448600T3 publication Critical patent/PL2448600T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10727003.5T 2009-07-03 2010-07-02 Związki ukierunkowane na kationoniezależny receptor mannozo-6-fosforanu PL2448600T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305647 2009-07-03

Publications (1)

Publication Number Publication Date
PL2448600T3 true PL2448600T3 (pl) 2016-10-31

Family

ID=41279432

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10727003.5T PL2448600T3 (pl) 2009-07-03 2010-07-02 Związki ukierunkowane na kationoniezależny receptor mannozo-6-fosforanu

Country Status (7)

Country Link
US (1) US8962573B2 (pl)
EP (1) EP2448600B1 (pl)
JP (1) JP5837486B2 (pl)
CA (1) CA2766614C (pl)
ES (1) ES2576853T3 (pl)
PL (1) PL2448600T3 (pl)
WO (1) WO2011000958A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
DK2613798T4 (en) 2010-09-09 2018-04-16 Synageva Biopharma Corp USING LYSOSOMAL SUR LIPASE TO TREAT PATIENTS WITHOUT LYSOSOMAL SUR LIPASE
US9138465B2 (en) 2011-04-28 2015-09-22 Osaka University Pharmaceutical composition for treating lysosomal storage disease
CN103958676A (zh) * 2011-10-12 2014-07-30 辛那杰瓦生物制药股份有限公司 重组人naglu蛋白质及其用途
DK3421051T3 (da) 2012-08-16 2020-06-22 Pfizer Fremgangsmåder til glycokonjugering og sammensætninger
CN102993256B (zh) * 2012-12-31 2016-05-18 浙江大学 一种选择性脱除全三甲基硅基保护糖的伯位三甲基硅基的方法
HK1220693A1 (zh) * 2013-03-15 2017-05-12 Newlink Genetics Corporation 碳水化合物改性的糖蛋白及其用途
FR3041345B1 (fr) * 2015-09-18 2019-06-14 Nanomedsyn Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
PL3833358T3 (pl) * 2018-08-10 2024-03-04 New York University Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmu
MX2021001596A (es) * 2018-08-10 2021-06-08 Univ New York Uso de manosa-6-fosfato y sus modificaciones para mejorar la memoria y reducir el daño mental.
US20220023434A1 (en) * 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
CA3167272A1 (en) * 2020-01-10 2021-07-15 Lycia Therapeutics, Inc. Cell surface receptor binding compounds and conjugates
WO2021263061A2 (en) * 2020-06-24 2021-12-30 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction
EP4171659A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
FR3132634B1 (fr) 2022-02-15 2025-04-25 Nanomedsyn Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant
FR3146400B1 (fr) 2023-03-07 2026-01-30 Nanomedsyn Conjugués ciblant le récepteur du mannose 6-phosphate cation-indépendant et le tissu osseux
FR3149188A1 (fr) 2023-05-31 2024-12-06 Nanomedsyn Pro-ligands, conjugués comprenant lesdits pro-ligands et leurs utilisations pour des applications thérapeutiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532384A (ja) 1998-10-08 2002-10-02 ステイヒテイング・ボール・デ・テヒニシエ・ベテンシヤツペン 星状細胞のためのペプチドを基剤としたキャリヤーデバイス
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7365178B2 (en) 2003-04-01 2008-04-29 Activx Biosciences, Inc. Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis
DE60319354T2 (de) 2003-07-11 2009-03-26 Lbr Medbiotech B.V. Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
AU2005258281A1 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
JP5069920B2 (ja) * 2007-02-08 2012-11-07 公益財団法人東京都医学総合研究所 マンノース6−リン酸−ポリエチレングリコール結合体
WO2008125615A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18 f-labelled folates
EP2192924B1 (en) 2007-08-20 2017-10-11 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof

Also Published As

Publication number Publication date
CA2766614A1 (en) 2011-01-06
JP2012531458A (ja) 2012-12-10
JP5837486B2 (ja) 2015-12-24
ES2576853T3 (es) 2016-07-11
US8962573B2 (en) 2015-02-24
EP2448600A1 (en) 2012-05-09
WO2011000958A1 (en) 2011-01-06
US20120093795A1 (en) 2012-04-19
CA2766614C (en) 2018-06-19
EP2448600B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
GB0918579D0 (en) Gadd45beta targeting agents
IL206654A0 (en) Combination therapy
ZA201200767B (en) Targeted immunoconjugates
ZA201009220B (en) 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides
GB0905184D0 (en) Encryption scheme
ZA201100101B (en) Universal atomizer
PL2239374T3 (pl) Wykańczarka
EP2451776A4 (en) N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS
PL2168690T3 (pl) Urządzenie do nasypywania korundu
GB2468970B (en) Improved couplings
PL2350553T3 (pl) Kołnierz balistyczny
GB201003308D0 (en) Targeting apparatus
GB0915244D0 (en) Re-post
GB2488464B (en) Moisturing composition
GB2472202B (en) Space heater
GB0916997D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0907973D0 (en) Combination therapy
PL2322716T3 (pl) Wykańczarka
IL202410A0 (en) Camouflage system
HU0900007V0 (en) Cheque
GB0814023D0 (en) Direct heater
GB0813292D0 (en) Therapy
GB0812659D0 (en) Therapy
PL387897A1 (pl) Grzejnik radiacyjno-konwekcyjny